Pandemic COVID-19:Current status and challenges of antiviral therapies

作     者：Winglam Chan Betsy He Xiong Wang Ming-Liang He 

作者机构：Department of Biomedical SciencesCity University of Hong KongHong KongChina Rensselaer Polytechnic InstituteTroyNYUSA CityU Shenzhen Research InstituteNanshanShenzhenChina 

出 版 物：《Genes & Diseases》 (基因与疾病（英文）)

年 卷 期：2020年第7卷第4期

页      面：502-519页

核心收录：

学科分类：0710[理学-生物学] 0831[工学-生物医学工程（可授工学、理学、医学学位）] 1004[医学-公共卫生与预防医学(可授医学、理学学位)] 1002[医学-临床医学] 1001[医学-基础医学(可授医学、理学学位)] 100201[医学-内科学(含：心血管病、血液病、呼吸系病、消化系病、内分泌与代谢病、肾病、风湿病、传染病)] 0703[理学-化学] 100401[医学-流行病与卫生统计学] 10[医学] 

基　　金：The work was partially supported by grants from The Science Technology and Innovation Committee of Shenzhen Municipality[JCYJ20170818100531426,JCYJ20180507181627057] grants from National Science Foundation of China Strategic funds from City University of Hong Kong 

主　　题：Chloroquine Convalescent plasma therapy COVID-19 Hydroxychloroquine Ivermectin Natural killer cell therapy Remdesivir SARS-CoV-2 

摘      要：The pandemic COVID-19,caused by a new coronavirus SARS-CoV-2 infection,has infected over 12 million individuals and caused more than 55,200 death ***,there is no specific drug to treating this *** we summarized the mechanisms of antiviral therapies and the clinic findings from different *** chemotherapies have been conducted by in multiple cohorts in different *** FDA has fast approved remdesivir for treating COVID-19,it only speeds up recovery from COVID-19 with mildly reduced *** chloroquine was suggested a potential drug against SARS-CoV-2 infection due to its in vitro antiviral effects,it is imperative high-quality data from worldwide clinical trials are necessitated for an approved *** terms of hydroxychloroquine(HCQ)therapy,although WHO has stopped all the clinic trials due to its strong side-effects in COVID patients,large scale clinical trials with a long-term outcome follow-up may warrant HCQ and azithromycin combination in combating the *** plasma(CP)therapy suggested its safety use in SARS-CoV-2 infection;but both CP immunotherapy and NK cellular therapy must be manufactured and utilized according to scrupulous ethical and controlled conditions to guarantee a possible role of these products of human *** research should be conducted to define the exact mechanism of SARS-CoV-2 pathogenesis,suitable animal models or ex vivo human lung tissues aid in studying replication,transmission and spread of the novel viruses,thereby facilitating highly effective therapies.